Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study is a Phase I/II trial of a novel Indibulin dosing schedule for the treatment of
metastatic breast cancer. Eligible patients will have measurable or non-measurable,
metastatic or unresectable, locally advanced breast cancer and may have received any number
of prior therapies for their disease.
It is expected that the Phase I portion will enroll up to 20 patients and the Phase II
portion will enroll up to 45 patients.